Question explored with the scientific record
compare olanzapine vs Lurasidone. this in a med stack with .5mg clonazepam, 600mg gabapentin, 30mg mirtazapine, 10mg belsomra - all meds taken in the evening
The short version: olanzapine is the stronger drug but the heavier metabolic burden; lurasidone is the lighter option, and with your stack, that difference matters.
The retrieved evidence is almost entirely about olanzapine, not lurasidone. No head-to-head trial of the two appears in these records, so the comparison rests on what each is known to do, with olanzapine's profile well documented here and lurasidone's drawn from general clinical knowledge outside this retrieval.
Olanzapine's metabolic risks are the standout finding. In the CATIE trial, olanzapine caused about 9.4 lbs of weight gain versus roughly 1 lb for quetiapine and risperidone, and about 30% of patients gained over 7% of their body weight [1]. It raised cholesterol, triglycerides, and HbA1c significantly [1]. A 2013 review found olanzapine and clozapine most linked to weight gain, with 50–80% of antipsychotic patients gaining weight overall [3]. In bipolar patients specifically, olanzapine produced greater weight gain than haloperidol [2]. Olanzapine also carries a nearly 5-fold higher risk of hyperlipidemia versus no antipsychotic exposure [6].
Your evening stack already includes mirtazapine, gabapentin, and suvorexant—all sedating. Olanzapine adds somnolence on top (37.5% in one pain study) [8], and betahistine was shown to reduce both olanzapine weight gain and sleepiness, suggesting these are real, modifiable effects [7]. Lurasidone is generally weight-neutral and less sedating, which matters when you are already taking three other sedating agents.
| Drug | Weight gain | Metabolic risk | Sedation |
|---|---|---|---|
| Olanzapine | ~9.4 lbs (CATIE) [1] | High; raises lipids, glucose [1][6] | High [8] |
| Lurasidone | Generally neutral (outside retrieval) | Low (outside retrieval) | Low (outside retrieval) |
The evidence here does not include a single lurasidone study, so its profile rests on general knowledge, not these records. What is clear: olanzapine's metabolic harms are documented and substantial, and your stack already carries sedation and metabolic load from mirtazapine and gabapentin.
My call: if you need maximum antipsychotic efficacy, olanzapine wins on symptom control [4][5], but lurasidone is the safer choice for this specific stack, given the metabolic and sedative overlap. Confidence: moderate—olanzapine's risks are well-evidenced here; lurasidone's benefits are not covered by this retrieval.
Sources used 8
-
Metabolic Findings From the CATIE Trial and Their Relation to Tolerability
Metabolic findings from the CATIE trial indicate high metabolic syndrome prevalence in schizophrenia, with olanzapine and other antipsychotics driving weight gain and dyslipidemia, impacting tolerability and necessitating routine metabolic monitoring.
DOI: 10.1017/s1092852900026663 -
2643 – Metabolic Syndrome and Antipsychotic Treatment: How about Schizophrenia and Bipolar Disorder?
Olanzapine treatment in bipolar disorder was associated with higher metabolic syndrome prevalence, different onset timing, and greater weight gain compared with schizophrenia patients on haloperidol or olanzapine.
DOI: 10.1016/s0924-9338(13)77274-2 -
Antipsychotic Drugs Opposite to Metabolic Risk: Neurotransmitters, Neurohormonal and Pharmacogenetic Mechanisms Underlying with Weight Gain and Metabolic Syndrome
Antipsychotic drugs, particularly second-generation agents such as clozapine and olanzapine, induce weight gain and metabolic syndrome through neurotransmitter, neurohormonal, and pharmacogenetic mechanisms, and require metabolic monitoring in treated patients.
DOI: 10.2174/1874205x01307010023 -
<p>A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future</p>
A narrative commentary reviewing the efficacy and safety profile of olanzapine for schizophrenia across illness stages, highlighting its potential advantages in long-term treatment persistence and symptom control despite significant metabolic risks, based on synthesis of major c…
DOI: 10.2147/NDT.S209284 -
Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials
A comprehensive network meta-analysis of 56 randomized controlled trials (n = 10,177) comparing 18 antipsychotics and placebo for long-term relapse prevention in schizophrenia, finding olanzapine and several long-acting injectable agents to provide favorable relapse reduction wi…
DOI: 10.1192/bjpo.bp.115.002576 -
Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management
This narrative review concludes that atypical antipsychotics carry clinically important metabolic risks in bipolar disorder—weight gain, glucose dysregulation, dyslipidemia, and hyperprolactinemia—with olanzapine and clozapine most implicated, and it provides monitoring and mana…
DOI: 10.1111/j.1399-2406.2003.00063.x -
Betahistine decreases olanzapine-induced weight gain and somnolence in humans
This study demonstrates that high doses of betahistine can significantly reduce weight gain and somnolence associated with olanzapine treatment in healthy women, suggesting a potential therapeutic strategy for managing these side effects.
DOI: 10.1177/0269881115626349 -
Efficacy and adverse effects of olanzapine in the treatment of moderate to severe refractory neuropathic pain*
In 40 patients with moderate-to-severe refractory cancer neuropathic pain, adding low-dose olanzapine to conventional analgesia reduced mean NRS pain scores by 2.575 at 3 days and 3.400 at 2 weeks, and PSQI by 4.725 at 2 weeks, with only mild adverse effects.
DOI: 10.1007/s10330-020-0401-1